Latest Regulatory Approval News

Tasman Resources progresses exploration at Lake Torrens and Parkinson Dam projects while managing capital through a recent entitlement offer and loan repayments.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

Bayan Mining and Minerals Limited has announced a loyalty options offer, granting shareholders one option for every four shares held, exercisable at $0.075 until late 2027. This move aims to incentivize shareholder engagement while potentially raising capital.

Mineral Commodities Ltd faces ongoing delays in the sale of its Skaland Graphite asset amid partial payments and defaults, while advancing negotiations to fully acquire the Munglinup Graphite Project. Operational challenges and financial pressures underscore a pivotal phase for the company’s battery minerals strategy.

Northern Minerals reports strong progress on its Browns Range Heavy Rare Earths Project with key regulatory approvals, promising exploration results, and near-completion of its Definitive Feasibility Study amid tightening global supply.

Prominence Energy has made a bold strategic move into the natural hydrogen and helium sector by agreeing to acquire a vast exploration portfolio in South Australia’s Gawler Craton, backed by a $1.75 million capital raise.

Great Boulder Resources reports a busy quarter with extensive drilling at Side Well and a robust scoping study at Ironbark, highlighting strong project economics and a recent $12.5 million capital raise.

Gibb River Diamonds has secured a contract mining agreement for its Edjudina Gold Project, aiming to start open pit mining at the Neta Prospect by August 2025, subject to permit approvals. The deal minimizes financial risk while positioning the company to capitalise on gold production.

Prescient Therapeutics has raised nearly $10 million through a placement and share purchase plan to advance its promising PTX-100 targeted cancer therapy into pivotal clinical stages.

Comet Ridge Limited has made significant progress in its Mahalo Gas Hub development, advancing engineering design, certifying substantial new gas reserves, and securing extended financing to support a Final Investment Decision.

HALO Technologies reports $3.54 million in Q2 revenue with rising subscription income, progressing UK expansion pending FCA approval, and a $6.75 million capital raise nearing completion.

Imugene Limited reports strong clinical progress with its off-the-shelf CAR T therapy azer-cel achieving a 75% overall response rate in Phase 1b trials, alongside new patents and leadership appointments. The company also secured $22.5 million in fresh funding to advance pivotal trials.